Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Amicus Therapeutics: Q3 Earnings Snapshot AP - Tue Nov 4, 6:29AM CST

Amicus Therapeutics: Q3 Earnings Snapshot

FOLD : 9.60 (+1.91%)
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates GlobeNewswire - Tue Nov 4, 6:00AM CST

Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30...

FOLD : 9.60 (+1.91%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 GlobeNewswire - Fri Oct 31, 6:00AM CDT

PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...

FOLD : 9.60 (+1.91%)
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 GlobeNewswire - Thu Oct 23, 6:00AM CDT

PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025,...

FOLD : 9.60 (+1.91%)
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM GlobeNewswire - Mon Sep 8, 8:00AM CDT

PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from...

FOLD : 9.60 (+1.91%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 GlobeNewswire - Fri Aug 29, 6:00AM CDT

PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...

FOLD : 9.60 (+1.91%)
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators FinancialNewsMedia - Wed Aug 6, 7:31AM CDT

EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END

FOLD : 9.60 (+1.91%)
TNXP : 15.88 (-5.53%)
SNGX : 1.3295 (-1.52%)
CTOR : 1.2250 (+0.41%)
AMGN : 343.32 (+0.47%)
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators Newswire.ca - Wed Aug 6, 7:30AM CDT

/CNW/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging...

FOLD : 9.60 (+1.91%)
TNXP : 15.88 (-5.53%)
SNGX : 1.3295 (-1.52%)
CTOR : 1.2250 (+0.41%)
AMGN : 343.32 (+0.47%)
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire - Wed Aug 6, 7:30AM CDT

NetworkNewsWire Editorial Coverage

FOLD : 9.60 (+1.91%)
TNXP : 15.88 (-5.53%)
SNGX : 1.3295 (-1.52%)
CTOR : 1.2250 (+0.41%)
AMG : 250.84 (-0.16%)
AMGN : 343.32 (+0.47%)
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales Zacks Investment Research - Fri Aug 1, 11:56AM CDT

Amicus Therapeutics FOLD reported adjusted earnings of 1 cent per share for the second quarter of 2025, which missed the Zacks Consensus Estimate of 2 cents. The company had incurred a loss of 6 cents...

FOLD : 9.60 (+1.91%)
IMCR : 37.74 (+3.20%)
ARVN : 14.04 (+27.17%)
CRMD : 10.19 (+2.10%)

Barchart Exclusives

Are These Beaten-Down Bottom 100 Stocks to Buy Ready to Rebound? Barchart - 6 minutes ago
You know the markets are in a correction when 16 of the Bottom 100 Stocks to Buy have share prices over $10. Not all 16 beaten-down stocks are worth considering. These two might be. Here’s why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot